We are excited to announce a leadership change in ENOTTA Working Group 3, “Assay Standardisation and Structured Overview on Participating Hospitals/Research Centres.”
We extend our heartfelt gratitude to Prof. Silje Skrede for her outstanding leadership and contributions to this group. Under her guidance, we have made significant strides in assay standardisation and enhanced collaboration among our participating hospitals and research centres. Thank you, Prof. Skrede, for your unwavering dedication and remarkable achievements!
We are equally thrilled to welcome Dr. James Bluett from the University of Manchester as the new leader of Working Group 3. Dr. Bluett brings a wealth of experience and expertise to the role, and we are confident that his leadership will further advance our mission and objectives. We look forward to the innovative ideas and fresh perspectives he will bring to the team.
Dr James Bluett (MBBS, MRes, MSc, PhD; Orchid ID: https://orcid.org/0000-0001-5062-5779) is a senior clinical lecturer and honorary consultant in rheumatology at the University of Manchester. James has a specialist interest in interventions to improve treatment response in inflammatory arthritis and is an experienced chief investigator. In 2016 he completed his PhD investigating methotrexate adherence in rheumatoid arthritis and the genetics of methotrexate-pneumonitis.
Please join us in celebrating this transition and in thanking Prof. Skrede for her incredible work while warmly welcoming Dr. Bluett to his new role!
